Cargando…
Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review
Immune checkpoint inhibitors (ICIs) have increased modern anticancer armamentarium portfolios, with 15%–60% of cancer patients deriving clinical benefit while others progress, including some occurrences of accelerated progressions. ICIs have also introduced a new pattern of immune-related adverse ev...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cancer Intelligence
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8723746/ https://www.ncbi.nlm.nih.gov/pubmed/35047065 http://dx.doi.org/10.3332/ecancer.2021.1314 |